Got to remember, they did not require an ADVISORY board be
held which my understanding is done to address 'concerns'.
Think that if they get to this stage? It comes down to, does it
meet the fdas criteria to be approved. With the most important
ones to me being, its effective, it works and it doesn't hurt folks
to use it. From what I can tell, it 'meets' these expectations.
The concern I have is primarily cause this is the first one I have held
for a decision related to combatting 'pain'.
Market Data 
Markets 
AI
